Samuel J. Klempner, MD, FASCO, on Advanced HER2-Negative Gastroesophageal Cancer: Ivonescimab Plus FOLFOX

May 31, 2026 By The ASCO Post Staff

Samuel J. Klempner, MD, FASCO, of Mass General Brigham Cancer Institute, discusses a single-arm phase II study—which is currently open and enrolling (ClinicalTrials.gov identifier NCT07070466)—evaluating ivonescimab in combination with FOLFOX as front-line therapy in locally advanced, unresectable, or metastatic HER2-negative gastroesophageal adenocarcinoma (Abstract TPS4246).

Related Content